Research priorities for the secondary prevention and management of acute rheumatic fever and rheumatic heart disease: A National Heart, Lung, and Blood Institute workshop report

Ganesan Karthikeyan; David Watkins; Gene Bukhman; Madeleine W. Cunningham; John Haller; Mary Masterson; George A. Mensah; Ana Mocumbi; Babu Muhamed; Emmy Okello; Nona Sotoodehnia; Tafadzwa Machipisa; Anna Ralph; Rosemary Wyber; Andrea Beaton

doi:10.1136/bmjgh-2023-012468

Research priorities for the secondary prevention and management of acute rheumatic fever and rheumatic heart disease: A National Heart, Lung, and Blood Institute workshop report

Ganesan Karthikeyan, David Watkins, Gene Bukhman, Madeleine W. Cunningham, John Haller, Mary Masterson, George A. Mensah, Ana Mocumbi, Babu Muhamed, Emmy Okello, Nona Sotoodehnia, Tafadzwa Machipisa, Anna Ralph, Rosemary Wyber, Andrea Beaton

Global and Tropical Health

Research output: Contribution to journal › Review article › peer-review

4 Citations (Scopus)

52 Downloads (Pure)

Abstract

Secondary prevention of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) involves continuous antimicrobial prophylaxis among affected individuals and is recognised as a cornerstone of public health programmes that address these conditions. However, several important scientific issues around the secondary prevention paradigm remain unresolved. This report details research priorities for secondary prevention that were developed as part of a workshop convened by the US National Heart, Lung, and Blood Institute in November 2021. These span basic, translational, clinical and population science research disciplines and are built on four pillars. First, we need a better understanding of RHD epidemiology to guide programmes, policies, and clinical and public health practice. Second, we need better strategies to find and diagnose people affected by ARF and RHD. Third, we urgently need better tools to manage acute RF and slow the progression of RHD. Fourth, new and existing technologies for these conditions need to be better integrated into healthcare systems. We intend for this document to be a reference point for research organisations and research sponsors interested in contributing to the growing scientific community focused on RHD prevention and control.

Original language	English
Article number	e012468
Pages (from-to)	1
Number of pages	10
Journal	BMJ Global Health
Volume	8
Issue number	9 S
DOIs	https://doi.org/10.1136/bmjgh-2023-012468
Publication status	Published - 31 Oct 2023

Bibliographical note

Funding Information:
AB, DW and NS received funding support from the National Institutes of Health. AB received funding support from American Heart Association, Leducq Foundation, Edwards Lifesciences—Every Heartbeat Matters, The Philips Foundation and Thrasher Pediatric Research Fund. MWC received fees as a consultant for Vaxform Incorporated, Serum India Institute and Pfizer Incorporated. MWC is the chief scientific officer and cofounder, with financial interest, in Moleculera Labs, a commercial laboratory for diagnostic testing of autoantibodies against the heart and brain. AR received funding support from the National Health and Medical Research Council. TM received funding support from the Population Health Research Institute (PHRI) & McMaster University, University of Cape Town and University of Witwatersrand.

Publisher Copyright:
© Author(s) (or their employer(s)) 2023.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/bmjgh-2023-012468

91164216-oaFinal published version, 500 KBLicence: CC BY-NC
91165408-oaFinal published version, 500 KBLicence: CC BY-NC

https://gh.bmj.com/content/8/Suppl_9/e012468

Cite this

Karthikeyan, G., Watkins, D., Bukhman, G., Cunningham, M. W., Haller, J., Masterson, M., Mensah, G. A., Mocumbi, A., Muhamed, B., Okello, E., Sotoodehnia, N., Machipisa, T., Ralph, A., Wyber, R., & Beaton, A. (2023). Research priorities for the secondary prevention and management of acute rheumatic fever and rheumatic heart disease: A National Heart, Lung, and Blood Institute workshop report. BMJ Global Health, 8(9 S), 1. Article e012468. https://doi.org/10.1136/bmjgh-2023-012468

@article{219ac28f3a074e959351d44a79f5c3d8,

title = "Research priorities for the secondary prevention and management of acute rheumatic fever and rheumatic heart disease: A National Heart, Lung, and Blood Institute workshop report",

abstract = "Secondary prevention of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) involves continuous antimicrobial prophylaxis among affected individuals and is recognised as a cornerstone of public health programmes that address these conditions. However, several important scientific issues around the secondary prevention paradigm remain unresolved. This report details research priorities for secondary prevention that were developed as part of a workshop convened by the US National Heart, Lung, and Blood Institute in November 2021. These span basic, translational, clinical and population science research disciplines and are built on four pillars. First, we need a better understanding of RHD epidemiology to guide programmes, policies, and clinical and public health practice. Second, we need better strategies to find and diagnose people affected by ARF and RHD. Third, we urgently need better tools to manage acute RF and slow the progression of RHD. Fourth, new and existing technologies for these conditions need to be better integrated into healthcare systems. We intend for this document to be a reference point for research organisations and research sponsors interested in contributing to the growing scientific community focused on RHD prevention and control.",

author = "Ganesan Karthikeyan and David Watkins and Gene Bukhman and Cunningham, {Madeleine W.} and John Haller and Mary Masterson and Mensah, {George A.} and Ana Mocumbi and Babu Muhamed and Emmy Okello and Nona Sotoodehnia and Tafadzwa Machipisa and Anna Ralph and Rosemary Wyber and Andrea Beaton",

note = "Funding Information: AB, DW and NS received funding support from the National Institutes of Health. AB received funding support from American Heart Association, Leducq Foundation, Edwards Lifesciences—Every Heartbeat Matters, The Philips Foundation and Thrasher Pediatric Research Fund. MWC received fees as a consultant for Vaxform Incorporated, Serum India Institute and Pfizer Incorporated. MWC is the chief scientific officer and cofounder, with financial interest, in Moleculera Labs, a commercial laboratory for diagnostic testing of autoantibodies against the heart and brain. AR received funding support from the National Health and Medical Research Council. TM received funding support from the Population Health Research Institute (PHRI) & McMaster University, University of Cape Town and University of Witwatersrand. Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2023.",

year = "2023",

month = oct,

day = "31",

doi = "10.1136/bmjgh-2023-012468",

language = "English",

volume = "8",

pages = "1",

journal = "BMJ Global Health",

issn = "2059-7908",

publisher = "BMJ Publishing Group",

number = "9 S",

}

Karthikeyan, G, Watkins, D, Bukhman, G, Cunningham, MW, Haller, J, Masterson, M, Mensah, GA, Mocumbi, A, Muhamed, B, Okello, E, Sotoodehnia, N, Machipisa, T, Ralph, A, Wyber, R & Beaton, A 2023, 'Research priorities for the secondary prevention and management of acute rheumatic fever and rheumatic heart disease: A National Heart, Lung, and Blood Institute workshop report', BMJ Global Health, vol. 8, no. 9 S, e012468, pp. 1. https://doi.org/10.1136/bmjgh-2023-012468

Research priorities for the secondary prevention and management of acute rheumatic fever and rheumatic heart disease: A National Heart, Lung, and Blood Institute workshop report. / Karthikeyan, Ganesan; Watkins, David; Bukhman, Gene et al.
In: BMJ Global Health, Vol. 8, No. 9 S, e012468, 31.10.2023, p. 1.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Research priorities for the secondary prevention and management of acute rheumatic fever and rheumatic heart disease

T2 - A National Heart, Lung, and Blood Institute workshop report

AU - Karthikeyan, Ganesan

AU - Watkins, David

AU - Bukhman, Gene

AU - Cunningham, Madeleine W.

AU - Haller, John

AU - Masterson, Mary

AU - Mensah, George A.

AU - Mocumbi, Ana

AU - Muhamed, Babu

AU - Okello, Emmy

AU - Sotoodehnia, Nona

AU - Machipisa, Tafadzwa

AU - Ralph, Anna

AU - Wyber, Rosemary

AU - Beaton, Andrea

N1 - Funding Information: AB, DW and NS received funding support from the National Institutes of Health. AB received funding support from American Heart Association, Leducq Foundation, Edwards Lifesciences—Every Heartbeat Matters, The Philips Foundation and Thrasher Pediatric Research Fund. MWC received fees as a consultant for Vaxform Incorporated, Serum India Institute and Pfizer Incorporated. MWC is the chief scientific officer and cofounder, with financial interest, in Moleculera Labs, a commercial laboratory for diagnostic testing of autoantibodies against the heart and brain. AR received funding support from the National Health and Medical Research Council. TM received funding support from the Population Health Research Institute (PHRI) & McMaster University, University of Cape Town and University of Witwatersrand. Publisher Copyright: © Author(s) (or their employer(s)) 2023.

PY - 2023/10/31

Y1 - 2023/10/31

N2 - Secondary prevention of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) involves continuous antimicrobial prophylaxis among affected individuals and is recognised as a cornerstone of public health programmes that address these conditions. However, several important scientific issues around the secondary prevention paradigm remain unresolved. This report details research priorities for secondary prevention that were developed as part of a workshop convened by the US National Heart, Lung, and Blood Institute in November 2021. These span basic, translational, clinical and population science research disciplines and are built on four pillars. First, we need a better understanding of RHD epidemiology to guide programmes, policies, and clinical and public health practice. Second, we need better strategies to find and diagnose people affected by ARF and RHD. Third, we urgently need better tools to manage acute RF and slow the progression of RHD. Fourth, new and existing technologies for these conditions need to be better integrated into healthcare systems. We intend for this document to be a reference point for research organisations and research sponsors interested in contributing to the growing scientific community focused on RHD prevention and control.

AB - Secondary prevention of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) involves continuous antimicrobial prophylaxis among affected individuals and is recognised as a cornerstone of public health programmes that address these conditions. However, several important scientific issues around the secondary prevention paradigm remain unresolved. This report details research priorities for secondary prevention that were developed as part of a workshop convened by the US National Heart, Lung, and Blood Institute in November 2021. These span basic, translational, clinical and population science research disciplines and are built on four pillars. First, we need a better understanding of RHD epidemiology to guide programmes, policies, and clinical and public health practice. Second, we need better strategies to find and diagnose people affected by ARF and RHD. Third, we urgently need better tools to manage acute RF and slow the progression of RHD. Fourth, new and existing technologies for these conditions need to be better integrated into healthcare systems. We intend for this document to be a reference point for research organisations and research sponsors interested in contributing to the growing scientific community focused on RHD prevention and control.

UR - http://www.scopus.com/inward/record.url?scp=85177465075&partnerID=8YFLogxK

U2 - 10.1136/bmjgh-2023-012468

DO - 10.1136/bmjgh-2023-012468

M3 - Review article

SN - 2059-7908

VL - 8

SP - 1

JO - BMJ Global Health

JF - BMJ Global Health

IS - 9 S

M1 - e012468

ER -

Research priorities for the secondary prevention and management of acute rheumatic fever and rheumatic heart disease: A National Heart, Lung, and Blood Institute workshop report

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this